The Asian cancer market was valued at $1.4bn in 2004, representing growth of 28.0% over year previous sales of $1.1bn; the rate of growth of the Asian cancer market is increasing rapidly, with current rates of growth outstripping the average growth rate of the previous 5 years: the size of the cancer patient population is forecast to increase over the period 2005-2010, and is primarily driven by increasing trends in the prevalence of breast, uterine, colorectal and lung cancer across the Asian region. Lung cancer is estimated to be responsible for the greatest number of cancer-related deaths over the nine Asian cancer markets. Breast cancer is the most common type of cancer developed by women and the leading cause of cancer-related mortality among women. Across the region of analysis, uterine cancer is estimated to feature the third highest incidence of the major cancers, at 233,070 in 2004, although mortality rates are forecast to fall slowly over the forecast period due to the implementation of stronger screening processes in China and India. Colorectal cancer is the fourth most commonly developed cancer across these nine Asian countries, after lung, breast, and uterine cancers. Prostate cancer had an estimated incidence of 39,161 individuals in 2004, which is forecast to rise to 41,263 in 2010. With low or delayed diagnosis, pancreatic cancer is believed to be the most deadly type of cancer, with a very low survival rate.